COVID-19 INFO #1: Data Collection
AplusA teams have been receiving questions regarding the impact of COVID-19 on market research...
COVID-19 Message of Thanks to AplusA Healthcare Professional Study Participants
Doctor Christine Maï, AplusA Executive Vice-President, sent the following message to the healthcare...
AplusA COVID-19 Business Continuity Plan
In light of the current global COVID-19 outbreak, we wanted to share key points from AplusA's...
DLBCL Case Study: Enhancing Patient Journey Research with Social Media Listening
hemato-oncology, DLBCL market, Social Media Listening, Syndicated Studies, Oncology
Using the example of a recent AplusA study in Diffuse Large B-Cell Lymphoma (DLBCL), we consider...
Patient Insights from AplusA’s Multiple Myeloma Tracker
hemato-oncology, Tracking Studies, Syndicated Studies, Oncology
A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the...
Multiple Myeloma Market Dynamics Revealed by AplusA Tracker
hemato-oncology, Tracking Studies, Syndicated Studies, Oncology
A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the...
Brand Performance Insights from AplusA's Multiple Myeloma Tracker
hemato-oncology, Tracking Studies, Syndicated Studies, Oncology
A thoughtfully developed tracker can provide deep insights on any therapeutic area. Using the...
Key Insights from a Multiple Myeloma Tracker
hemato-oncology, Tracking Studies, Syndicated Studies, Oncology